Evidence map›Paper›PMID 38838644›Full record

ArticleCell metabolism2024

Imaging brain glucose metabolism in vivo reveals propionate as a major anaplerotic substrate in pyruvate dehydrogenase deficiency.

Isaac Marin-Valencia, Arif Kocabas, Carlos Rodriguez-Navas, Vesselin Z Miloushev, Manuel González-Rodríguez, Hannah Lees, Kelly E Henry, Jake Vaynshteyn, Valerie Longo, Kofi Deh and 4 more

Abstract read
In one paragraph

Article in Cell metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Isaac Marin-ValenciaThe Abimael Laboratory of Neurometabolism, Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Laboratory of Developmental Neurobiology, The Rockefeller University, New York, NY, USA. Electronic address: isaac.marin-valencia@mssm.edu.
Arif KocabasThe Abimael Laboratory of Neurometabolism, Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Carlos Rodriguez-NavasThe Abimael Laboratory of Neurometabolism, Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Vesselin Z MiloushevRadiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Manuel González-RodríguezThe Abimael Laboratory of Neurometabolism, Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Hannah LeesRadiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kelly E HenryRadiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jake VaynshteynThe Abimael Laboratory of Neurometabolism, Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Valerie LongoSmall Animal Imaging Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kofi DehRadiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Roozbeh EskandariRadiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA.
Arsen MamakhanyanRadiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marjan BerishajRadiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kayvan R KeshariRadiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: rahimikk@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Leveraging fructose transport to create a privileged substrate to selectively fuel T cellsR01CA248364 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Kayvan R Keshari · 2021 to 2026
$4.3M
Development of large-field-of-view hyperpolarized MRIR01CA237466 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CUNNINGHAM, CHARLES H., HRICAK, HEDVIG · 2020 to 2024
$3.4M
Visualizing oxidative stress using hyperpolarized magnetic resonanceR01CA252037 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KESHARI, KAYVAN R · 2020 to 2024
$3.3M
Mechanisms and Therapies for Cerebellar Development Under Defective Mitochondrial MetabolismK08NS110877 · NINDS · ROCKEFELLER UNIVERSITY · PI MARIN-VALENCIA, ISAAC · 2019 to 2023
$999k
uCoil NMR platform for robust and high-throughput analysis of in vitro metabolic flux on living cellsR21CA212958 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KESHARI, KAYVAN R · 2017 to 2019
$660k
Upgrade of 800 MHz SpectrometerS10OD016432 · OD · NEW YORK STRUCTURAL BIOLOGY CENTER · PI PALMER, ARTHUR G · 2014 to 2014
$600k
Acquisition of an 800 MHz TXO CryoProbeS10OD028577 · OD · NEW YORK STRUCTURAL BIOLOGY CENTER · PI PALMER, ARTHUR G · 2020 to 2020
$299k
A New Therapy for Neurodevelopmental Mitochondrial DisordersR21NS133826 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MARIN-VALENCIA, ISAAC · 2024 to 2025
$211k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA237466NCI NIH HHS R01 CA248364NCI NIH HHS R01 CA252037NCI NIH HHS R21 CA212958NIH HHS S10 OD016432NIH HHS S10 OD028577NINDS NIH HHS K08 NS110877NINDS NIH HHS R21 NS133826
6 · The paper itself

Abstract

A vexing problem in mitochondrial medicine is our limited capacity to evaluate the extent of brain disease in vivo. This limitation has hindered our understanding of the mechanisms that underlie the imaging phenotype in the brain of patients with mitochondrial diseases and our capacity to identify new biomarkers and therapeutic targets. Using comprehensive imaging, we analyzed the metabolic network that drives the brain structural and metabolic features of a mouse model of pyruvate dehydrogenase deficiency (PDHD). As the disease progressed in this animal, in vivo brain glucose uptake and glycolysis increased. Propionate served as a major anaplerotic substrate, predominantly metabolized by glial cells. A combination of propionate and a ketogenic diet extended lifespan, improved neuropathology, and ameliorated motor deficits in these animals. Together, intermediary metabolism is quite distinct in the PDHD brain-it plays a key role in the imaging phenotype, and it may uncover new treatments for this condition.

Indexed as

BrainGlucosePropionatesPyruvate Dehydrogenase Complex Deficiency DiseaseAnimalsDiet, KetogenicDisease Models, AnimalGlycolysisMaleMiceMice, Inbred C57BLGlucosePropionatesbrainglucoseimagingketogenic dietmetabolismpropionatepyruvatepyruvate dehydrogenase deficiency

Identifiers

PMID38838644
PMCPMC11187753

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.